ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,011.12
      -0.22%
      US Tech 100
      16,815.60
      -0.71%
      Dow Jones
      37,775.38
      0.06%
      Brent Oil
      85.84
      -0.67%
      Bitcoin
      64,907.34
      2.20%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NeuroSense Therapeutics Ltd (NRSN)

      7. NeuroSense Therapeutics Ltd (NRSN) News

      NRSN NeuroSense Therapeutics Ltd

      1.52
      0.00 (0.00%)
      Pre Market
      Last Updated: 05:41:30
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      NeuroSense Therapeutics Ltd NRSN NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      0.00 0.00% 1.52 05:41:30
      Open Price Low Price High Price Close Price Prev Close
      1.52
      more quote information »

      Recent News

      Date Time Source Heading
      4/18/202408:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
      4/12/202408:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
      4/10/202419:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
      4/09/202408:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
      4/05/202409:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
      2/22/202408:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/21/202408:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
      2/13/202413:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/13/202410:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/07/202409:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/07/202409:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
      1/09/202408:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/09/202408:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/09/202408:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
      12/27/202317:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
      12/27/202317:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/27/202317:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
      12/21/202308:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/14/202316:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
      12/14/202309:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/14/202309:24PRNUSNeuroSense Reports New Data: Statistically Significant..
      12/05/202315:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
      12/05/202315:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
      12/05/202308:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/05/202308:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
      12/05/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
      12/04/202316:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
      12/04/202306:17EDGAR2Form POS AM - Post-Effective amendments for registration..
      11/28/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/28/202308:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
      11/21/202310:36EDGAR2Form POS AM - Post-Effective amendments for registration..
      11/13/202309:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/13/202309:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
      11/09/202309:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
      11/06/202308:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/06/202308:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
      11/01/202309:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
      10/17/202308:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/17/202308:30PRNUSNeuroSense CEO Provides Q3 2023 Update
      10/04/202309:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/04/202309:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
      10/02/202311:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/20/202309:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/20/202309:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
      9/19/202309:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/19/202309:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
      9/14/202309:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
      9/12/202309:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/07/202316:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
      9/06/202308:30PRNUSNeuroSense to Host Investor Webinar on September 12, 2023

      Your Recent History

      NASDAQ
      NRSN
      NeuroSense Therapeutics
      Delayed Upgrade Clock